Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics Inc. is positioned favorably in the biopharmaceutical market due to its innovative development of TH103, a novel anti-VEGF drug, which demonstrates superior retinal retention compared to current market leader Eylea, potentially translating to longer-lasting therapeutic effects. The strong market performance of similar anti-VEGF drugs, exemplified by Vabysmo's exceeding $4 billion in global sales within three years and capturing significant market share, underscores the potential for substantial revenue growth in this sector. Furthermore, preclinical findings showing TH103's complete inhibition of VEGF-induced endothelial cell proliferation indicate promising efficacy, generating optimism around its advancement through clinical trials and subsequent market introduction.

Bears say

Kalaris Therapeutics Inc., as a development-stage biotechnology company, has not yet commercialized any products and will require substantial infrastructure investments to launch and market its therapeutic candidate, TH103. The company is expected to continue incurring significant net losses until it achieves commercialization, which may be further exacerbated by potential delays in clinical development and regulatory approvals. Additionally, strong competition from both established and emerging therapies poses a risk to Kalaris's market penetration and pricing, which may hinder its financial performance and outlook.

Allovir Inc (KLRS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Allovir Inc (KLRS) has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.